Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Race Oncology Ltd. ( (AU:RAC) ) has provided an announcement.
Race Oncology Ltd has announced its 2025 Annual General Meeting, scheduled for November 24, 2025, at the State Library NSW in Sydney. The company has provided shareholders with a letter, notice of the meeting, and proxy form, emphasizing the importance of shareholder engagement and participation. This meeting is a key event for stakeholders to discuss the company’s strategic direction and operational updates.
More about Race Oncology Ltd.
Race Oncology Ltd is an ASX-listed clinical stage biopharmaceutical company focused on cancer care. Its lead asset, RCDS1, is a small molecule anticancer agent targeting cancer growth regulator MYC. The company is developing a proprietary formulation, RC220, for multiple oncology indications and exploring partnerships to enhance global patient access.
Average Trading Volume: 450,620
Technical Sentiment Signal: Buy
Current Market Cap: A$724M
See more data about RAC stock on TipRanks’ Stock Analysis page.